Catheter with specialized nanosensors could enable earlier detection of bladder cancer, MIT study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

While treatment is often successful, bladder cancer has one of the highest rates of recurrence of any cancer: Following treatment, about 50% of patients develop tumors again within the next five years. This makes it one of the most expensive cancers for society to treat.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The European Commission has granted Marketing Authorization for Padcev (enfortumab vedotin), in combination with Keytruda (pembrolizumab), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer in the European Union, regardless of cisplatin eligibility.
A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose people with bladder cancer more accurately than current standard methods. The test also allows physicians to not only assess the cancer’s response to treatment but to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login